Journal
FRONTIERS IN MOLECULAR BIOSCIENCES
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmolb.2022.931759
Keywords
nanoparticles; ocular drug delivery; toxicity; assessment; challenges
Categories
Funding
- National Natural Science Foundation of China [81873688]
- National Key Research and Development Program of China [2018YFA0107302]
- Natural Science Foundation of Chongqing [cstc2021jcyj-msxmX0171]
Ask authors/readers for more resources
Nanotechnology has rapidly developed and been widely applied in ocular disease therapy. Nano-drug delivery systems show strong biocompatibility and efficiency, but also potential toxicity, which needs to be evaluated through experiments for safety verification.
Nanotechnology has been developed rapidly in recent decades and widely applied in ocular disease therapy. Nano-drug delivery systems overcome the bottlenecks of current ophthalmic drug delivery and are characterized with strong biocompatibility, stability, efficiency, sustainability, controllability, and few side effects. Nanoparticles have been identified as a promising and generally safe ophthalmic drug-delivery system based on the toxicity assessment in animals. Previous studies have found that common nanoparticles can be toxic to the cornea, conjunctiva, and retina under certain conditions. Because of the species differences between humans and animals, advanced in vitro cell culture techniques, such as human organoids, can mimic the human organism to a certain extent, bringing nanoparticle toxicity assessment to a new stage. This review summarizes the advanced application of nanoparticles in ocular drug delivery and the potential toxicity, as well as some of the current challenges and future opportunities in nanotoxicological evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available